argenx SE (MEX:ARGX) Debt-to-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is argenx SE Debt-to-Asset?

argenx SE's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was MXN0 Mil. argenx SE's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was MXN0 Mil. argenx SE's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was MXN0 Mil.

argenx SE Debt-to-Asset Historical Data

The historical data trend for argenx SE's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Debt-to-Asset Chart

argenx SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

argenx SE Quarterly Data
	Jun19	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	0.01	-

Competitive Comparison of argenx SE's Debt-to-Asset

For the Biotechnology subindustry, argenx SE's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

argenx SE's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where argenx SE's Debt-to-Asset falls into.

argenx SE Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

argenx SE's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(78.862	+	260.623)	/	77104.809
	=	0.00

argenx SE's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	0
	=	N/A

argenx SE (MEX:ARGX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

argenx SE Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of argenx SE's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (MEX:ARGX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ARGX:USA ARGXb:UK 0QW0:UK 1AE:Germany A1RG34:Brazil ARGX:Belgium

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.